WATCH: Daniel Heng, MD, MPH, FRCPC, (@DrDanielHeng) highlights final results from LITESPARK-011, which evaluated belzutifan plus lenvatinib vs cabozantinib in patients with advanced ccRCC following anti-PD-(L)1 therapy. #ESMO26 https://www.urologytimes.com/view/daniel-heng-md-highlights-final-litespark-011-results-in-advanced-ccrcc